Skip to main content
Top
Published in: Arthritis Research & Therapy 4/2009

01-08-2009 | Letter

Cytokines in the colon of a patient with Behçet's disease

Authors: Jasper H Kappen, Willem A Dik, Gemma M Dingjan, Paul L van Daele, Herbert Hooijkaas, P Martin van Hagen, Jan A van Laar

Published in: Arthritis Research & Therapy | Issue 4/2009

Login to get access

Excerpt

We read with interest the article by Cañete and colleagues [1] in a recent issue of Arthritis Research & Therapy, in which they describe cytokine patterns of inflamed joints from patients with Behçet's disease (BD). The authors show that neutrophils and T lymphocytes are involved in a Th1-skewed inflammatory pattern expressed by elevations of interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and interleukin-2 (IL-2). Also, increased levels of IL-4, IL-10, and IL-17 were observed. We would like to add to these observations our data showing a similar cytokine profile in the colon of a patient with BD. …
Appendix
Available only for authorised users
Literature
1.
go back to reference Cañete JD, Celis R, Noordenbos T, Moll C, Gómez-Puerta JA, Pizcueta P, Palacin A, Tak PP, Sanmartí R, Baeten D: Distinct synovial immunopathology in Behçet disease and psoriatic arthritis. Arthritis Res Ther. 2009, 11: R17-10.1186/ar2608.PubMedCentralCrossRefPubMed Cañete JD, Celis R, Noordenbos T, Moll C, Gómez-Puerta JA, Pizcueta P, Palacin A, Tak PP, Sanmartí R, Baeten D: Distinct synovial immunopathology in Behçet disease and psoriatic arthritis. Arthritis Res Ther. 2009, 11: R17-10.1186/ar2608.PubMedCentralCrossRefPubMed
2.
go back to reference Dik WA, Nadel B, Przybylski GK, Asnafi V, Grabarczyk P, Navarro JM, Verhaaf B, Schmidt CA, Macintyre EA, van Dongen JJ, Langerak AW: Different chromosomal breakpoints impact the level of LMO2 expression in T-ALL. Blood. 2007, 110: 388-392. 10.1182/blood-2006-12-064816.CrossRefPubMed Dik WA, Nadel B, Przybylski GK, Asnafi V, Grabarczyk P, Navarro JM, Verhaaf B, Schmidt CA, Macintyre EA, van Dongen JJ, Langerak AW: Different chromosomal breakpoints impact the level of LMO2 expression in T-ALL. Blood. 2007, 110: 388-392. 10.1182/blood-2006-12-064816.CrossRefPubMed
3.
go back to reference Yazici H, Fresko I, Yurdakul S: Behçet's syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol. 2007, 3: 148-155. 10.1038/ncprheum0436.CrossRefPubMed Yazici H, Fresko I, Yurdakul S: Behçet's syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol. 2007, 3: 148-155. 10.1038/ncprheum0436.CrossRefPubMed
4.
go back to reference van Laar JA, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM: Adalimumab: a new modality for Behçet's disease?. Ann Rheum Dis. 2007, 66: 565-566. 10.1136/ard.2006.064279.PubMedCentralCrossRefPubMed van Laar JA, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM: Adalimumab: a new modality for Behçet's disease?. Ann Rheum Dis. 2007, 66: 565-566. 10.1136/ard.2006.064279.PubMedCentralCrossRefPubMed
Metadata
Title
Cytokines in the colon of a patient with Behçet's disease
Authors
Jasper H Kappen
Willem A Dik
Gemma M Dingjan
Paul L van Daele
Herbert Hooijkaas
P Martin van Hagen
Jan A van Laar
Publication date
01-08-2009
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 4/2009
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar2784

Other articles of this Issue 4/2009

Arthritis Research & Therapy 4/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine